Table 1.
Patient characteristics, driver mutation status, and PD‐L1 TPS
| Characteristics | No. of patients |
|---|---|
| Gender | |
| Male | 106 (44.0%) |
| Female | 135 (56.0%) |
| Age (years) | |
| Median | 56 |
| Range | 24–77 |
| Smoking history | |
| Never | 145 (60.2%) |
| Current/former | 96 (39.8%) |
| Histology | |
| Adenocarcinoma | 229 (95.0%) |
| Squamous cell carcinoma | 8 (3.3%) |
| Adenosquamous carcinoma | 4 (1.7%) |
| p stage | |
| IA | 40 (16.6%) |
| IB | 46 (19.1%) |
| IIA | 3 (1.2%) |
| IIB | 39 (16.2%) |
| IIIA | 91 (37.8%) |
| IIIB | 22 (9.1%) |
| EGFR status | |
| Wild‐type | 162 (67.2%) |
| Exon 19 deletion | 36 (14.9%) |
| Exon 21 L858R | 37 (15.4%) |
| Others† | 6 (2.5%) |
| KRAS status | |
| Wild‐type | 218 (90.5%) |
| Mutated | 23 (9.5%) |
| PD‐L1 TPS | |
| < 1% | 153 (63.5%) |
| 1–49% | 53 (22.0%) |
| ≥ 50% | 35 (14.5%) |
†
Others: exon 18, S768I and insertion, exon 21 L861Q, complex mutation with exon 19 deletion + T790M.
TPS, tumor proportion score.